Oren Gilad

Company: Aprea Therapeutics

Job title: Chief Executive Officer

Seminars:

Adding On to Monotherapy: Combining DDR Inhibitors 1:30 pm

Combinations to combat emerging resistance; identifying combination agents Can the combination of DDRis result in overlapping toxicity? A case study of combining PARPi and ATRi Circumventing PLK inhibition: combining ATRN-W1051 with Wee1 or ATR inhibitorsRead more

day: Day Two

Understanding DDRi’s In the Clinic: Why is Toxicity Such a Big Issue? 8:30 am

On target vs off target toxicological effects; which inhibitors are more likely to result in off target side effects? How much inhibition is needed? Identifying the optimum therapeutic window Current strategies employed to minimize toxicological effects when designing clinical trialsRead more

day: Day Two

Panel Discussion: How Are Newer Targets Being Validated to Move Towards Clinical Trials? 4:15 pm

What is the rationale behind selecting novel targets for research? How do these targets differ from previous projects? What do these new targets offer to existing drug development projects?Read more

day: Day One